Summary
In the search for targeting MAPK plus other pathways in NRAS-mutant melanoma, a phase Ib/II trial tested binimetinib plus ribociclib in metastatic melanoma. The response rate in the phase II trial was 19.5%, and the median progression-free survival was 3.7 months.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.